

2019 Interim Financial Report

Lyon (France), September 30, 2019 - AMOEBA (FR0011051598 -AMEBA), producer of biological biocides capable of eliminating bacterial risks in water and human wounds, and a biocontrol product for plant protection, still in trial phase, announces today that it has published its Interim Financial Report for 2019.

AMOÉBA's shareholders are informed that the interim financial report for the 2019 financial year (ending on December 31st, 2019), filed today with the Autorité des Marchés Financiers (AMF), can be found at the company website: <http://www.amoeba-biocide.com/en/regulatories-information-and-financial-documents>.

This report includes:

- Interim Activity Report
- Condensed Interim Financial Statements
- Certification of the person responsible for the interim financial report
- Statutory Auditors' Review Report on the interim financial information



About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn ⁽¹⁾ on a global chemical biocide market for water treatment, evaluated at €21Bn ⁽²⁾ and on the biocontrol market for plant protection estimated globally at €1.6Bn ⁽⁴⁾. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million ⁽³⁾ in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedomia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017



(4): *Biopesticides Worldwide Market 2013, CPL, Wallingford, UK*

Contacts:

Amoéba

Valérie FILIATRE

General Manager

+33 (0)4 26 69 16 00

valerie.filiatre@amoeba-biocide.com

Investors Relations

Grégory BOSSON

Agence Calyptus

+33(0)1 53 65 37 90

gregory.bosson@calyptus.net

Medias relations

Constance LOZET

Agence Ekno

+33(0)7 78 41 19 70

constance.lozet@ekno.fr

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 25, 2019 under number D19-0383 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.